

RECEIVED
CENTRAL FAX CENTER

JUN 12 2008

Seed^{IP}

June 12, 2008

Facsimile Transmission**Julie A. Urvater, Ph.D.****Patent Agent****Telephone: (206) 622-4900****julieu@SeedIP.com**

To: Examiner Cynthia B. Wilder, Ph.D.
US Patent & Trademark Office, GAO 1637

Fax No.: 571.273.8300**Phone No.:** 571.272.0791**Re: Discussion Points for Telephone Interview of June 16, 2008****Your Ref.:** US Application Nos. 10/550,797 and 11/392,479**Seed IP Ref.:** 210121.609USPC and 210121.609C1**No. of Pages:** 3 (including this page)

address 701 Fifth Avenue
Suite 5400
Seattle, WA 98104
telephone 206.622.4900
facsimile 206.682.6031
website SeedIP.com

If you do not receive all pages, please call Monica Satterthwaite at (206) 812-4454 or fax our office.

 Urgent For Review Please Confirm
Receipt Please Reply
ASAP**Comments:****Examiner Wilder:**

Per your request, attached is a summary of discussion points for our telephone interview of the noted applications, scheduled for Monday, June 16, 2008 at 1 p.m. DC time/10 a.m. Seattle time. Please let me know if you need additional information.

Julie A. Urvater, Ph.D.,**Transmission Information:****Date:****Time:****By:****CONFIDENTIALITY NOTICE:**

The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the addressee named above. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.

RECEIVED
JUN 12 2008

FOR DISCUSSION ONLY
DISCUSSION POINTS FOR TELEPHONE INTERVIEW OF JUNE 16, 2008

Application No. : 10/550,797 and 11/392,479

For : DETECTION AND MONITORING OF LUNG CANCER

Examiner : Cynthia B. Wilder, Ph.D.

Fax : 571-273-0791

Art Unit : 1637

Docket No. : 210121.609USPC & 210121.609C1

USSN 10/550,797

- The Action asserts at page 5 that Applicant appears to be arguing “efficiency”. Discuss “complementarity” of the recited markers versus “efficiency”.
 - The present method detects greater than 90% of lung tumors, a level of detection that is not possible using the biomarkers individually. While the individual markers may have been known in the art, taken individually, they do not have this level of sensitivity.
- The Action asserts at page 5 that the presence of lung cancer is only recognized if one of the markers is elevated.
 - The method as presently claimed requires measuring the level of expression of at least two markers though detecting the expression of just one in a sample indicates the presence of lung cancer. Discuss potential claim amendment to clarify. (e.g., recite “three or more” or similar language; and/or recite “measuring the level of mRNA expression...”)

JUN 12 2008

FOR DISCUSSION ONLY

DISCUSSION POINTS FOR TELEPHONE INTERVIEW OF JUNE 16, 2008

Application No. : 10/550,797 and 11/392,479
For : DETECTION AND MONITORING OF LUNG CANCER

Examiner : Cynthia B. Wilder, Ph.D.
Fax : 571-273-0791
Art Unit : 1637
Docket No. : 210121.609USPC & 210121.609C1

USSN 11/392,479

- Discuss "complementarity" of the recited markers versus "efficiency".
- Discuss the concept that the present composition detects greater than 90% of lung tumors, a level of detection that is not possible using the markers individually. While the individual markers may have been known in the art, taken individually, they do not have this level of sensitivity.
- Henderson *et al* discloses over 2000 sequences. While the specification may have generic language indicating that multiple markers can be used in combination, given the complete lack of specific teaching therein, the skilled artisan would not know which of the 2000 sequences to combine in order to achieve the high level of sensitivity of lung cancer detection of the presently claimed composition.

As a note: the Action asserts that SEQ ID NO:1868 of Henderson *et al* refers to the L762P antigen. However, this sequence refers to L984P (see Henderson *et al* paragraph [0933]). To our knowledge, Henderson *et.al* do not disclose the sequence of L762P.